{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:04:48Z","timestamp":1784909088540,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymgmr.2026.101324","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:37:48Z","timestamp":1780418268000},"page":"101324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A 53-week, open-label phase IIIb study of velaglucerase alfa in Chinese patients with type 1 Gaucher disease: Safety, efficacy, and pharmacokinetics"],"prefix":"10.1016","volume":"47","author":[{"given":"Lihui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Qun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengkui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaco","family":"Botha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2026.101324_bb0005","series-title":"Williams Hematology","article-title":"Gaucher disease and related lysosomal storage diseases","author":"Revel-Vilk","year":"2021"},{"key":"10.1016\/j.ymgmr.2026.101324_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0015","article-title":"An overview of Gaucher disease","volume":"14","author":"Mendez-Cobian","year":"2024","journal-title":"Diagnostics (Basel)."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2024.11.001","article-title":"Emerging biomarkers in Gaucher disease","volume":"124","author":"Luettel","year":"2025","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010085","article-title":"Global incidence and prevalence of Gaucher disease: a targeted literature review","volume":"12","author":"Castillon","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0030","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/jhg.2017.36","article-title":"Successful newborn screening for Gaucher disease using fluorometric assay in China","volume":"62","author":"Kang","year":"2017","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0035","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13023-021-01830-4","article-title":"Demographics, in-hospital analysis, and prevalence of 33 rare diseases with effective treatment in Shanghai","volume":"16","author":"Cai","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0040","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5582\/irdr.2022.01093","article-title":"Incidence and prevalence of 121 rare diseases in China: current status and challenges: 2022 revision","volume":"11","author":"Lu","year":"2022","journal-title":"Intract. Rare Dis. Res."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cca.2014.01.030","article-title":"Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan","volume":"431","author":"Liao","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgmr.2026.101324_bb0050","doi-asserted-by":"crossref","first-page":"e2410754","DOI":"10.1001\/jamanetworkopen.2024.10754","article-title":"Newborn screening for 6 lysosomal storage disorders in China","volume":"7","author":"Chang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ymgmr.2026.101324_bb0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13073-025-01483-z","article-title":"Effect of newborn genomic screening for lysosomal storage disorders: a cohort study in China","volume":"17","author":"Wang","year":"2025","journal-title":"Genome Med."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13023-018-0782-x","article-title":"A pilot screening of high-risk Gaucher disease children using dried blood spot methods in Shandong province of China","volume":"13","author":"Lei","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0065","series-title":"Velaglucerase Alfa for Injection, Approved 27 April 2021","year":"2021"},{"key":"10.1016\/j.ymgmr.2026.101324_bb0070","series-title":"Eliglustat Tartrate Capsules, Approved 10 October 2022","year":"2022"},{"key":"10.1016\/j.ymgmr.2026.101324_bb0075","series-title":"Imiglucerase for Injection, Approved 26 October 2023","year":"2023"},{"key":"10.1016\/j.ymgmr.2026.101324_bb0080","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s13023-021-02119-2","article-title":"Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan","volume":"16","author":"Sagara","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bcmd.2016.10.026","article-title":"Clinical and molecular characteristics of patients with Gaucher disease in southern China","volume":"68","author":"Feng","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0090","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/gim.2016.159","article-title":"Early manifestations of type 1 Gaucher disease in presymptomatic children diagnosed after parental carrier screening","volume":"19","author":"Yang","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cca.2020.03.016","article-title":"High risk screening for Gaucher disease in patients with splenomegaly and\/or thrombocytopenia in China: 55 cases identified","volume":"506","author":"Huang","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgmr.2026.101324_bb0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2007.02.008","article-title":"A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated\u00ae human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease","volume":"39","author":"Zimran","year":"2007","journal-title":"Blood Cell Mol. Dis."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0105","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0110","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.23383","article-title":"Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","volume":"88","author":"Zimran","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bcmd.2016.03.004","article-title":"Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease","volume":"59","author":"Pastores","year":"2016","journal-title":"Blood Cell Mol. Dis."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0120","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymgmr.2026.101324_bb0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcmd.2016.10.007","article-title":"Treatment-naive Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials","volume":"68","author":"Zimran","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13123588","article-title":"Twelve years of the Gaucher outcomes survey (GOS): insights, achievements, and lessons learned from a global patient registry","volume":"13","author":"Elstein","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0135","doi-asserted-by":"crossref","first-page":"E140","DOI":"10.1002\/ajh.25074","article-title":"Glucosylsphingosine is a reliable response biomarker in Gaucher disease","volume":"93","author":"Arkadir","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0140","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.3390\/ijms21134577","article-title":"Treatment efficiency in Gaucher patients can reliably be monitored by quantification of Lyso-Gb1 concentrations in dried blood spots","volume":"21","author":"Cozma","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2017.08.005","article-title":"Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naive and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: data from phase 3 clinical trials","volume":"122","author":"Elstein","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0150","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s13023-022-02549-6","article-title":"An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan","volume":"17","author":"Ida","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","article-title":"Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention","volume":"103","author":"Boot","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ymgmr.2026.101324_bb0160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bcmd.2005.05.005","article-title":"Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease","volume":"35","author":"Deegan","year":"2005","journal-title":"Blood Cell Mol. Dis."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0165","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ajh.24007","article-title":"Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease","volume":"90","author":"Elstein","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0170","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ajh.24040","article-title":"Seven-year safety and efficacy with velaglucerase alfa for treatment-na\u00efve adult patients with type 1 Gaucher disease","volume":"90","author":"Zimran","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1189\/jlb.1204712","article-title":"Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes","volume":"78","author":"Schutyser","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ymgmr.2026.101324_bb0180","first-page":"3397","article-title":"An analysis of mutations causing Gaucher disease in Chinese population","volume":"89","author":"Zhang","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.ymgmr.2026.101324_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12062220","article-title":"The bone biomarker of quantitative chemical shift imaging in patients with type 1 Gaucher disease receiving low-dose long-term enzyme replacement therapy","volume":"12","author":"Zimran","year":"2023","journal-title":"J. Clin. Med."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426926000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426926000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:17:23Z","timestamp":1784906243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426926000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"alternative-id":["S2214426926000364"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2026.101324","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A 53-week, open-label phase IIIb study of velaglucerase alfa in Chinese patients with type 1 Gaucher disease: Safety, efficacy, and pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2026.101324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Takeda Pharmaceuticals International AG. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101324"}}